

BIOLOGICS, BIOSIMILARS & RHEUMATIC DISEASE



- About **58.5 million** Americans have arthritis.

BIOLOGICAL MEDICATIONS

BIOLOGICS

Made from natural and living sources.
More complex than other drugs.



BIOSIMILARS

Follow-on medicines.
Similar to originator biologics with no clinically meaningful differences.

INTERCHANGEABLE BIOSIMILARS

Must meet a higher FDA standard.
May be substituted without consulting the prescriber.



Of surveyed rheumatologists:



98% are familiar with biosimilars

90% feel comfortable prescribing biosimilars



The first rheumatology biosimilar was approved by the Food & Drug Administration in 2016.

Rheumatology treatments were among the first biosimilars ever approved.



17 BIOSIMILARS

including one interchangeable, are approved for:

Rheumatoid Arthritis
Juvenile Idiopathic Arthritis
Psoriatic Arthritis
Ankylosing Spondylitis
Polyarticular Juvenile Idiopathic Arthritis
Plaque Psoriasis



bpc

BiologicsPrescribers
COLLABORATIVE
A PROJECT OF AfPA

www.BiologicsPrescribers.org

Sources: American College of Rheumatology
Food and Drug Administration
Cardinal Health Specialty Solutions
Centers for Disease Control and Prevention